Shah Navin, Ioffe Vladimir
Mid-Atlantic Urology Associates Greenbelt, MD.
21st Century Oncology Greenbelt, MD.
Rev Urol. 2020;22(3):102-109.
To compare prostate biopsy (Pbx) characteristics before and after the 2012 United States Preventive Services Task Force (USPSTF) prostate cancer (PCa) screening guidelines, we completed a retrospective comparative analysis of 1703 sequential patients that had a Pbx in 2010 to 2012 (3 years) with 383 patients biopsied in 2018 and 310 patients biopsied in 2019. Data was collected on patient age, race, serum prostate specific antigen (PSA) level, digital rectal examination (DRE) results, total number of biopsies performed, and Gleason sum score (GSS). Data were analyzed to determine whether the 2012 USPSTF screening recommendations against PCa screening may have affected PCa characteristics. Three study groups were defined as Group A, Group B, and Group C. Group A represents Pbx prior to the 2012 USPSTF screening guidelines (2010-2012), Group B represents Pbx in 2018, and Group C represents Pbx in 2019. The patient population consisted of 73% Black men, 16% White men, and 11% men of other races. The number of patients that had a biopsy in Groups A through C, respectively, were 567 patients/year, 383 patients/year, and 310 patients/year. The annual positive Pbx rate for Group A through C was 134/year, 175/year, and 201/year, respectively. High-grade PCa (GSS 7-10) in Groups A through C was 51.5%, 60.5%, and 60.0%. The proportion of patients with a serum PSA level 10 ng/mL or greater in Groups A through C was 25.4%, 29.3%, and 33%. For patients age 70 to 80 years, there was an increasing trend for serum PSA levels 10 ng/mL and higher: 31%, 38%, and 39%, respectively. In this age group, high-grade tumors (GSS 7-10) occurred in 61%, 65%, and 68%, respectively. In 2019, Grade Group 3, 4, and 5 was present in 37.7% of 70- to 80-year-old men and 34.6% of Black men. More than 50% positive biopsy cores were present in 46.3% of 70- to 80-year old men and 36.6% of Black men. Our data through 2019 continued to show that after the 2012 USPSTF recommendations against PCa screening, PCa screening has decreased. We found decreased Pbx, increased PCa diagnosis, and increased high-grade PCa (GSS 7-10). As our patient population consisted of 73% Black patients and 33% of men age 70 to 80 years, our results support aggressive PCa screening for high-risk patients, which include Black men, men with a family history of PCa, and healthy men age 70 to 80 years.
为比较2012年美国预防服务工作组(USPSTF)前列腺癌(PCa)筛查指南前后的前列腺活检(Pbx)特征,我们对2010年至2012年(3年)接受Pbx的1703例连续患者与2018年活检的383例患者及2019年活检的310例患者进行了回顾性对比分析。收集了患者年龄、种族、血清前列腺特异性抗原(PSA)水平、直肠指检(DRE)结果、活检总数及Gleason总分(GSS)等数据。对数据进行分析以确定2012年USPSTF针对PCa筛查的建议是否可能影响了PCa特征。三个研究组分别定义为A组、B组和C组。A组代表2012年USPSTF筛查指南之前(2010 - 2012年)的Pbx,B组代表2018年的Pbx,C组代表2019年的Pbx。患者群体包括73%的黑人男性、16%的白人男性和11%的其他种族男性。A组至C组接受活检的患者数量分别为每年567例、每年383例和每年310例。A组至C组每年的活检阳性率分别为每年134例、每年175例和每年201例。A组至C组的高级别PCa(GSS 7 - 10)分别为51.5%、60.5%和60.0%。A组至C组血清PSA水平为10 ng/mL或更高的患者比例分别为25.4%、29.3%和33%。对于70至80岁的患者,血清PSA水平为10 ng/mL及更高呈现上升趋势:分别为31%、38%和39%。在这个年龄组中,高级别肿瘤(GSS 7 - 10)分别占61%、65%和68%。2019年,70至80岁男性中有37.7%以及黑人男性中有34.6%存在3级、4级和5级分级组。70至80岁男性中有46.3%以及黑人男性中有36.6%的活检核心阳性数超过50%。我们截至2019年的数据持续表明,在2012年USPSTF提出反对PCa筛查的建议后,PCa筛查有所减少。我们发现Pbx减少、PCa诊断增加以及高级别PCa(GSS 7 - 10)增加。由于我们的患者群体包括73%的黑人患者以及33%的70至80岁男性,我们的结果支持对高危患者进行积极的PCa筛查,这些高危患者包括黑人男性、有PCa家族史的男性以及70至80岁的健康男性。